Literature DB >> 9886071

Site-specific dephosphorylation of tau of apolipoprotein E-deficient and control mice by M1 muscarinic agonist treatment.

I Genis1, A Fisher, D M Michaelson.   

Abstract

Apolipoprotein E (apoE)-deficient mice have memory deficits that are associated with synaptic loss of basal forebrain cholinergic projections and with hyperphosphorylation of distinct epitopes of the microtubule-associated protein tau. Furthermore, treatment of apoE-deficient mice with the M1 selective agonist 1-methylpiperidine-4-spiro-(2'-methylthiazoline) [AF150(S)] abolishes their memory deficits and results in recovery of their brain cholinergic markers. In the present study, we used a panel of anti-tau monoclonal antibodies to further map the tau epitopes that are hyperphosphorylated in apoE-deficient mice and examined the effects of prolonged treatment with AF150(S). This revealed that tau of apoE-deficient mice contains a distinct, hyperphosphorylated "hot spot" domain which is localized N-terminally to the microtubule binding domain of tau, and that AF150(S) has an epitope-specific tau dephosphorylating effect whose magnitude is affected by apoE deficiency. Accordingly, epitopes which reside in the hyperphosphorylated "hot spot" are dephosphorylated by AF150(S) in apoE-deficient mice but are almost unaffected in the controls, whereas epitopes which flank this tau domain are dephosphorylated by AF150(S) in both mice groups. In contrast, epitopes located at the N and C terminals of tau are unaffected by AF150(S) in both groups of mice. These findings suggest that apoE deficiency results in hyperphosphorylation of a distinct tau domain whose excess phosphorylation can be reduced by muscarinic treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9886071     DOI: 10.1046/j.1471-4159.1999.0720206.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  9 in total

1.  Apolipoprotein E knockout mice as a model of behavioral dysfunction.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

2.  Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease.

Authors:  Cassia R Overk; Christian C Felder; Yuan Tu; Doug A Schober; Kelly R Bales; Joanne Wuu; Elliott J Mufson
Journal:  J Chem Neuroanat       Date:  2010-03-27       Impact factor: 3.052

3.  Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice.

Authors:  I Tesseur; J Van Dorpe; K Spittaels; C Van den Haute; D Moechars; F Van Leuven
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 4.  Understanding How Physical Exercise Improves Alzheimer's Disease: Cholinergic and Monoaminergic Systems.

Authors:  Boyi Zong; Fengzhi Yu; Xiaoyou Zhang; Wenrui Zhao; Peng Sun; Shichang Li; Lin Li
Journal:  Front Aging Neurosci       Date:  2022-05-18       Impact factor: 5.702

Review 5.  Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease.

Authors:  Abraham Fisher
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

6.  In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors.

Authors:  Patrizia De Sarno; Gautam N Bijur; Anna A Zmijewska; Xiaohua Li; Richard S Jope
Journal:  Neurobiol Aging       Date:  2005-04-26       Impact factor: 4.673

7.  AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.

Authors:  Abraham Fisher; Rachel Brandeis; Rachel Haring Nira Bar-Ner; Michal Kliger-Spatz; Niva Natan; Hagar Sonego; Itzhak Marcovitch; Zipora Pittel
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

Review 8.  M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.

Authors:  Abraham Fisher; Zipora Pittel; Rachel Haring; Nira Bar-Ner; Michal Kliger-Spatz; Niva Natan; Inbal Egozi; Hagar Sonego; Itzhak Marcovitch; Rachel Brandeis
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 2.866

9.  The role of Wnt signaling in neuronal dysfunction in Alzheimer's Disease.

Authors:  Nibaldo C Inestrosa; Enrique M Toledo
Journal:  Mol Neurodegener       Date:  2008-07-24       Impact factor: 14.195

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.